Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Of Fulvestrant Plus Abemaciclib In Er-Positive, Her2-Negative Metastatic Breast Cancer Immediately After Failure Of A Cdk4/6 Inhibitor

NCT05305924 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT05305924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05305924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Of Fulvestrant Plus Abemaciclib In Er-Positive, Her2-Negative Metastatic Breast Cancer Immediately After Failure Of A Cdk4/6 Inhibitor
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 25, 2021
Completion date
December 1, 2027
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

er-positive breast cancer, her2-negative breast cancer